Clinical Trials Directory

Trials / Conditions / Lateral Canthal Lines

Lateral Canthal Lines

26 registered clinical trials studyying Lateral Canthal Lines.

StatusTrialSponsorPhase
CompletedTreatment of Moderate to Severe Lateral Canthal Lines
NCT04249687
Galderma R&DPhase 3
CompletedLong-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NCT04225260
Galderma R&DPhase 3
CompletedMT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686
Medy-ToxPhase 3
CompletedClinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
NCT04143854
Medy-ToxPhase 2
CompletedEfficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treat
NCT03911102
Revance Therapeutics, Inc.Phase 2
CompletedMT10109L in the Treatment of Lateral Canthal Lines
NCT03785145
Medy-ToxPhase 3
CompletedMT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03732833
Medy-ToxPhase 3
CompletedMT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Line
NCT03721016
Medy-ToxPhase 3
CompletedPrincess® RICH for the Correction of Fine Lines
NCT03923634
Croma-Pharma GmbHN/A
CompletedET-01 in Subjects With Lateral Canthal Lines, LCL-208
NCT03839693
Eirion Therapeutics Inc.Phase 2
CompletedET-01 in Subjects With Lateral Canthal Lines, LCL-207
NCT03655691
Eirion Therapeutics Inc.Phase 2
CompletedET-01 in Subjects With Lateral Canthal Lines
NCT03326856
Eirion Therapeutics Inc.Phase 2
CompletedSafety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in K
NCT02248844
Allergan—
CompletedBOTOX® in the Treatment of Crow's Feet Lines in China
NCT02195687
AllerganPhase 3
CompletedDose Finding Study In Subjects With Crow's Feet
NCT01951742
Anterios Inc.Phase 2
CompletedClinical Trial to Evaluate ANT-1401 in Crow's Feet
NCT01809964
Anterios Inc.Phase 2
CompletedClinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
NCT01358695
Anterios Inc.Phase 2
CompletedSafety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adu
NCT01124565
Revance Therapeutics, Inc.Phase 2
CompletedA 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Ad
NCT01124552
Revance Therapeutics, Inc.Phase 2
CompletedEfficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01064518
Revance Therapeutics, Inc.Phase 2
CompletedEfficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968942
Revance Therapeutics, Inc.Phase 2
CompletedSafety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968825
Revance Therapeutics, Inc.Phase 2
CompletedSafety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00907387
Revance Therapeutics, Inc.Phase 2
CompletedSafety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00884234
Revance Therapeutics, Inc.Phase 2
CompletedSafety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00888914
Revance Therapeutics, Inc.Phase 2
CompletedBotulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
NCT00247559
IpsenPhase 2